In colitis models, inhibition of RhoA/ROCK activity significantly protects the intestinal epithelial barrier dysfunction and colonic inflammation via STAT3 and NF-κB signaling pathways [22,23,24,25]. This evidence concerns the gene STAT3 and colitis.